NattoPharma
R&D
Research and Development
NattoPharma has a long term clinical program for MenaQ7 to investigate aspects of this very important compound in health and disease. MenaQ7 is supported by some of the most experienced vitamin K experts in the world, and we strive to substantiate our product and market information by scientific data and a broad knowledge in the vitamin K field.
The fascinating mechanisms of action for MenaQ7 implies that research is needed to further reveal its many benefits, to establish safe dosages for use in different clinical situations and to differentiate MenaQ7. NattoPharma is dedicated to do just that in partnerships with world experts and have signed a strategic 5-year R&D agreement with Professors Cees Vermeer of the Cardiovascular Research Institute Maastricht, University of Maastricht and VitaK BV. VitaK BV is the world's largest and leading research company in vitamin K.
This R&D agreement, along with contacts to other outstanding medical institutions, secures explorative as well as clinical results for NattoPharma’s present recommendations and future use of MenaQ7. We are proud and excited to follow and stimulate the research in the biochemical and clinical settings with regards to Vitamin K2.
Dr. Cees Vermeer – one of the world leading experts on Vitamin K2
Dr. Vermeer studied Biochemistry at Leiden, where he also presented his PhD thesis (1974) on the initiation of protein biosynthesis in E coli.
Contact Us
For futher information, please contact:
Dr. Vladimir Badmaev
Head of R&D
info@nattopharma.com
Created by:
